Thrombolex Inc.

Founded in 2016, Thrombolex, Inc. is engaged in the design, development, manufacture and distribution of innovative endovascular catheters.

03/08/2026

The BASHIR™ Plus Endovascular Device is designed for targeted thrombolytic delivery in peripheral vessels. The expandable infusion basket and variable distal-shaft infusion lengths provide procedural flexibility and controlled delivery to support safe and efficient treatment of venous thrombus.

Thrombolex.com

03/04/2026

Combining mechanical fragmentation and targeted lytic delivery, the BASHIR™ Plus Endovascular Device elevates treatment of venous thrombus while giving clinicians clinical confidence.

Thrombolex.com

03/01/2026

The BASHIR™ Endovascular Device is designed for precise pharmaco-mechanical lysis (PML) through on-the-table treatment. It delivers targeted thrombolytic therapy along with mechanical clot fragmentation, which helps restore blood flow safely and efficiently in the treatment of pulmonary embolism (PE).

Thrombolex.com

02/28/2026

Today at PEGASUS Endovascular, Vivian Bishay, MD will present a case of submassive pulmonary embolism (PE) treated with pharmaco-mechanical intervention using the BASHIR™ Endovascular Catheter.

The session begins today, Saturday, February 28 at 11:36 AM and will share real-world insights into procedural approach and targeted therapy in PE management. We hope you can join the meeting.

https://m3meet.com/pegasusendovascular-2026

Thrombolex.com

02/27/2026

Thrombolex will be at AVF 2026. As venous care evolves, we remain focused on delivering precise, targeted approaches that support procedural control and clinical confidence. We look forward to continuing the discussion with you at the conference.

Thrombolex.com

02/25/2026

Join Thrombolex at PEGASUS Endovascular for a virtual clinical case presentation on submassive pulmonary embolism (PE) treated with Pharmaco-Mechanical intervention using the BASHIR™ Endovascular Catheter.

Vivian Bishay, MD of Mount Sinai Hospital, NY will present this case, highlighting procedural considerations and the role of mechanical fragmentation and targeted thrombolysis in PE treatment.

https://m3meet.com/pegasusendovascular-2026

Thrombolex.com

02/24/2026

Thrombolex will be attending AVF 2026, booth #11. We look forward to engaging with the venous community and continuing conversations around targeted, thrombolytic therapy and procedural approaches that support safe, efficient treatment for venous disease.

Thrombolex.com

02/22/2026

The BASHIR™ Endovascular Device is designed for efficient placement, controlled mechanical fragmentation and targeted delivery of thrombolytics for the treatment of pulmonary embolism. Its 0.035"" guidewire compatibility supports procedural ease and speed while enabling on-the-table pharmaco-mechanical lysis (PML).

Thrombolex.com

02/20/2026

The RAPID-PE Study is a post-market, single-arm, multicenter study investigating on-the-table PML without post-procedural thrombolytic infusion using the BASHIR™ Endovascular Device. Interim results have shown that the approach can efficiently restore blood flow, eliminate ICU stays, and support safe recovery.

These findings emphasize Thrombolex’s commitment to real-world evidence, clinical confidence, and patient-centered therapies.

https://thrombolex.com/interim-data-from-the-rapid-pe-study-presented-at-tct-2025/

02/18/2026

Pulmonary Embolism remains a leading cause of preventable in-hospital mortality. Pharmaco-mechanical lysis (PML) is controlled mechanical fragmentation and targeted thrombolytics, this can restore blood flow quickly and reduce the burden on patients and providers.

At Thrombolex, our focus is on solutions that help clinicians deliver single-session treatment and improve patient outcomes.

02/16/2026

Effective PE treatment requires more than thrombolytics alone. By integrating mechanical action with targeted delivery, BASHIR™ Endovascular Devices enable controlled clot fragmentation while limiting thrombolytic exposure to where it is needed most.

Thrombolex.com

02/14/2026

The ongoing RAPID-PE Study demonstrates real-world safety and effectiveness in treating intermediate-risk pulmonary embolism. Using on-the-table pharmaco-mechanical lysis with the BASHIR™ Endovascular Device, interim data shows efficient blood flow restoration and low ICU utilization, supporting faster recovery and improved patient outcomes.

Thrombolex.com

Address

75 Britain Drive
New Britain, PA
18901

Telephone

+18447926300

Website

http://www.thrombolex.com/

Alerts

Be the first to know and let us send you an email when Thrombolex Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Thrombolex Inc.:

Shortcuts

Want your practice to be the top-listed Clinic in New Britain?